Avanos Medical (AVNS) Revenue & Revenue Breakdown
Avanos Medical Revenue Highlights
Latest Revenue (Y)
$687.80M
Latest Revenue (Q)
$177.80M
Main Segment (Y)
Digestive Health
Main Geography (Y)
UNITED STATES
Avanos Medical Revenue by Period
Avanos Medical Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $687.80M | 2.15% |
| 2023-12-31 | $673.30M | -17.89% |
| 2022-12-31 | $820.00M | 10.13% |
| 2021-12-31 | $744.60M | 4.17% |
| 2020-12-31 | $714.80M | 2.47% |
| 2019-12-31 | $697.60M | 6.94% |
| 2018-12-31 | $652.30M | 6.65% |
| 2017-12-31 | $611.60M | -61.59% |
| 2016-12-31 | $1.59B | 1.14% |
| 2015-12-31 | $1.57B | -5.84% |
| 2014-12-31 | $1.67B | -0.32% |
| 2013-12-31 | $1.68B | -0.39% |
| 2012-12-31 | $1.68B | 1.45% |
| 2011-12-31 | $1.66B | - |
Avanos Medical generated $687.80M in revenue during NA 2024, up 2.15% compared to the previous quarter, and up 98.60% compared to the same period a year ago.
Avanos Medical Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $177.80M | 1.60% |
| 2025-06-30 | $175.00M | 4.48% |
| 2025-03-31 | $167.50M | -6.74% |
| 2024-12-31 | $179.60M | 5.40% |
| 2024-09-30 | $170.40M | -0.76% |
| 2024-06-30 | $171.70M | 3.37% |
| 2024-03-31 | $166.10M | -4.15% |
| 2023-12-31 | $173.30M | 1.17% |
| 2023-09-30 | $171.30M | 1.12% |
| 2023-06-30 | $169.40M | 6.34% |
| 2023-03-31 | $159.30M | -12.28% |
| 2022-12-31 | $181.60M | 5.40% |
| 2022-09-30 | $172.30M | 0.82% |
| 2022-06-30 | $170.90M | -13.42% |
| 2022-03-31 | $197.40M | 2.07% |
| 2021-12-31 | $193.40M | 5.05% |
| 2021-09-30 | $184.10M | -1.23% |
| 2021-06-30 | $186.40M | 3.15% |
| 2021-03-31 | $180.70M | -2.32% |
| 2020-12-31 | $185.00M | -0.38% |
| 2020-09-30 | $185.70M | 13.44% |
| 2020-06-30 | $163.70M | -9.26% |
| 2020-03-31 | $180.40M | -4.95% |
| 2019-12-31 | $189.80M | 10.74% |
| 2019-09-30 | $171.40M | -0.46% |
| 2019-06-30 | $172.20M | 4.87% |
| 2019-03-31 | $164.20M | -3.35% |
| 2018-12-31 | $169.90M | 2.91% |
| 2018-09-30 | $165.10M | 2.61% |
| 2018-06-30 | $160.90M | 2.88% |
| 2018-03-31 | $156.40M | -126.75% |
| 2017-12-31 | $-584.60M | -245.64% |
| 2017-09-30 | $401.40M | 0.55% |
| 2017-06-30 | $399.20M | 0.91% |
| 2017-03-31 | $395.60M | -3.51% |
| 2016-12-31 | $410.00M | 3.14% |
| 2016-09-30 | $397.50M | -0.63% |
| 2016-06-30 | $400.00M | 3.95% |
| 2016-03-31 | $384.80M | -4.14% |
| 2015-12-31 | $401.40M | 3.06% |
| 2015-09-30 | $389.50M | 0.05% |
| 2015-06-30 | $389.30M | -1.24% |
| 2015-03-31 | $394.20M | -10.29% |
| 2014-12-31 | $439.40M | 7.56% |
| 2014-09-30 | $408.50M | -1.21% |
| 2014-06-30 | $413.50M | 0.68% |
| 2014-03-31 | $410.70M | -4.78% |
| 2013-12-31 | $431.30M | 2.81% |
| 2013-09-30 | $419.50M | 0.87% |
| 2013-06-30 | $415.90M | 1.24% |
| 2013-03-31 | $410.80M | - |
Avanos Medical generated $177.80M in revenue during Q3 2025, up 1.60% compared to the previous quarter, and up 103.55% compared to the same period a year ago.
Avanos Medical Revenue Breakdown
Avanos Medical Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| Interventional Pain | $167.30M | $162.50M | - | - | - |
| Digestive Health | $396.40M | $371.60M | - | - | - |
| Interventional pain | - | - | $183.60M | $102.10M | - |
| Digestive health | - | - | $340.40M | $322.20M | - |
| Chronic Care | - | - | $476.30M | $479.80M | $471.20M |
| Acute pain | - | - | $160.10M | $162.70M | - |
| Respiratory health | - | - | $135.90M | $157.60M | - |
| Pain Management | - | - | $343.70M | $264.80M | $243.60M |
Avanos Medical's latest annual revenue breakdown by segment (product or service), as of Dec 24: Digestive Health (70.32%), and Interventional Pain (29.68%).
Quarterly Revenue by Product
| Product/Service | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corporate Other | $4.80M | $11.30M | $10.20M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Digestive Health | - | - | - | $105.80M | $98.20M | $97.70M | $94.70M | $183.60M | $95.00M | $93.00M | - | - | - | - | - | - | - | - | - | - |
| Interventional pain | - | - | - | - | $41.90M | $41.70M | $40.20M | $42.20M | $41.60M | $35.80M | $47.40M | $47.50M | $49.50M | $39.30M | - | - | - | - | - | - |
| Acute pain | - | - | - | - | - | - | - | - | - | - | $34.70M | $41.30M | $38.90M | $41.20M | $38.70M | - | - | - | - | - |
| Chronic Care | - | - | - | - | - | - | - | - | - | - | $121.20M | $128.80M | $115.70M | $112.30M | $119.40M | $125.60M | $117.10M | $116.00M | $121.10M | $116.00M |
| Digestive health | - | - | - | - | - | - | - | - | - | - | $88.80M | $92.90M | $85.90M | $80.20M | $81.40M | - | - | - | - | - |
| Pain Management | - | - | - | - | - | - | - | - | - | - | $70.50M | $88.70M | $86.40M | $90.70M | $78.00M | $67.80M | $67.00M | $70.40M | $59.60M | $69.00M |
| Respiratory health | - | - | - | - | - | - | - | - | - | - | $32.40M | $35.90M | $29.80M | $32.10M | $38.00M | - | - | - | - | - |
Avanos Medical's latest quarterly revenue breakdown by segment (product or service), as of Sep 25: Corporate Other (100.00%).
Avanos Medical Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| UNITED STATES | $529.10M | $467.00M | $560.70M | $521.60M | $482.00M |
Avanos Medical's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (100.00%).
Avanos Medical Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CYH | Community Health Systems | $12.63B | $3.09B |
| VREX | Varex Imaging | $844.60M | $212.90M |
| AVNS | Avanos Medical | $687.80M | $177.80M |
| BVS | Bioventus | $573.28M | $138.65M |
| LAB | Standard BioTools | $174.43M | $19.55M |
| PACB | Pacific Biosciences of California | $154.01M | $38.44M |
| CTKB | Cytek Biosciences | $111.11M | $52.29M |
| CBLL | CeriBell | $45.23M | $22.59M |
| BCYC | Bicycle Therapeutics | $35.27M | $11.73M |
| CLPT | ClearPoint Neuro | $31.39M | $8.86M |
| FDMT | 4D Molecular Therapeutics | - | - |